

February 10, 2016

Bombay Stock Exchange Limited Corporate Relationship Department 1st floor, New Trading Ring Rotunda Building, P J Towers Dalal Street, Fort Mumbai - 400 001

**Sub: Press Release** 

Dear Sir/Madam,

Please find enclosed the Press Release issued in connection with Unaudited Financial Results of the Company for quarter/nine months ended December 31, 2015.

Kindly take it on your records.

Thanking you,


Yours faithfully,

L Chandrasekar

Executive V P - Finance & Secretary.

Encl.: a/a

CIN: L24222TN1992PLC022994



BSE: 524372 NSE: ORCHIDPHAR Bloomberg: ORCP:IN Reuters: ORCD.BO

## Q3 FY16 Earnings

**Chennai, India – Feb 10, 2016** 

Orchid Pharma registers turnover of Rs 204 crore in Q3 FY16, EBITDA of Rs 39 crore.

Financial highlights for Quarter ended December 31, 2015 (Q3 FY16) – Standalone

- Revenue of Rs 203.8 crore (US\$ 30.5 million) in the quarter ended December 31, 2015 (Q3 FY16) as compared to Rs 164.5 crore (US\$ 24.6 million) registered during the quarter ended December 31, 2014 (Q5 FY15).
- EBITDA of Rs 38.6 crore (US\$ 5.8 million) in the quarter ended December 31, 2015 as compared to Rs 27.1 crore (US\$ 4.1 million) in the quarter ended December 31, 2014
- At the net level, the company registered a loss of Rs 94.0 crore (US\$ 14.1 million) during the quarter ended December 31, 2015 as compared to a loss of Rs 120.1 crore (US\$ 17.9 million) for the corresponding quarter ended December 31, 2014.

## \* 1 US\$ = Rs 66.83


The operations of certain plants at the Alathur facility were affected in December 2015 on account of the heavy rains and flood. The Company has taken necessary steps to restore the operations within a month. Necessary claim for loss of materials and business interruption is being processed under the insurance coverage.

During the quarter ended December 31, 2015, the Company has entered into a long term financial arrangement which will help the Company explore new growth opportunities while enabling the current business achieve incremental value.

## From the Managing Director

"Despite the business interruption sustained on account of unprecedented torrential rains in December 2015, the Company is confident of regaining the traction on account of growth measures being initiated including launch of new products and long term financial arrangements", said Mr K Raghavendra Rao, Managing Director, Orchid Pharma Ltd.

'Orchid Towers', #313, Valluvar Kottam High Road, Nungambakkam, Chennai 600 034 INDIA



Page 1 of 2 Tel: +91 - 44- 2821 1000 Fax: +91 - 44 - 2821 1002

E-mail: corporate@orchidpharma.com Website: www.orchidpharma.com





## **About Orchid Pharma**

Orchid Pharma Ltd. (Formerly Orchid Chemicals & Pharmaceuticals Ltd.) is a leading pharmaceutical company headquartered in Chennai, India involved in the development; manufacture and marketing of diverse bulk actives, formulations and nutraceuticals. With exports spanning more than 75 countries, Orchid is the largest manufacturer-exporter of cephalosporin bulk actives in India and is ranked amongst the Top 5-cephalosporin producers in the world. Orchid's world-class manufacturing infrastructure including USFDA and UK MHRA approved API and dosage form facilities located at Chennai. Orchid has dedicated state-of-the-art GLP compliant R&D centres for API research, drug discovery and pharmaceutical research at Chennai. Orchid has ISO 14001 and OHSAS 18001 certifications. Orchid is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) in India.

Additional information is available at the company's website at www.orchidpharma.com

For ORCHID CHEMICALS & PHARMACEUTICALS LTD.

Executive Vice President - Finance & Secretary